Clinical features, pathogens, and prognosis of immunocompromised host pneumonia in patients with malignancies.

ABSTRACT:

Background

Cancer patients face elevated risks of severe pulmonary infections due to malignancy-related immunosuppression and anti-neoplastic therapy. Comprehensive data on the etiology and prognostic factors remain limited.

Methods

This prospective cohort study enrolled 115 patients with malignancies and immunocompromised host pneumonia (ICHP) from July 2023 to July 2024. Pathogens were identified using clinical metagenomics of bronchoalveolar lavage fluid (BALF), supported by CT imaging and clinical evaluation.

Results

Pathogens were detected in 92 patients (80.0%), with 158 potential pathogens detected. Etiologic diagnoses were established by BALF mNGS alone in 68 (73.9%), by combined mNGS plus standard microbiologic testing (SMT) in 24 (26.1%), and by SMT alone in

SUBMITTER: Fang XZ 

PROVIDER: S-EPMC12669106 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature